WESTMINSTER, Colo., Nov. 30, 2016 -- Surefire Medical, Inc. today announced that Mats Wahlström is joining the company’s Board of Directors and will serve as chairman. Wahlström has more than 30 years of experience in the healthcare industry, having served as CEO and CFO of large international companies in the medical field.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/cc59d0f8-0ea1-499b-abab-01f58ef1aa3f
“Surefire Medical is honored to have Mats join our board and serve as our Chairman,” said James E. Chomas, CEO and President of Surefire Medical. “His business acumen and experience in the medical device industry will be an essential asset to Surefire reaching our strategic objectives and helping propel our company forward as we strive to invent the future for cancer care.”
Wahlström currently serves as Executive Chairman of KMG Capital Partners, LLC, Chairman of PCI | HealthDev, and Chairman of Caduceus Medical Holdings, Inc. He also serves as the Lead Director and Chairman of the Audit/Finance Committee of Coherus Biosciences, a public biotech company. In addition, he currently serves on the boards of Getinge AB and Alteco Medical AB, both public companies, as well as Triomed AB and Circuit Clinical, Inc.
From March 2009 through its sale to a private equity firm in October 2010, Wahlström served as a director of Health Grades, Inc., a NASDAQ-listed healthcare ratings company. Also from January 2004 through December 2009, Wahlström served as Co-CEO of Fresenius Medical Care North America, and from November 2002 through December 2009 as President and CEO of Fresenius Medical Services, which operates more than 1,700 dialysis clinics in the U.S. Prior to joining Fresenius Medical Care in 2002, he held various positions at Gambro AB in Sweden, including President and CEO of Gambro North America as well as CFO of the Gambro Group.
Surefire’s current Board Chair, Norman Weldon, will continue to serve on the Surefire Board of Directors.
About Surefire Medical
Surefire Medical, Inc. develops, manufactures and markets innovative infusion systems for the Interventional Radiology and Interventional Oncology markets. Surefire’s technology is designed to precisely deliver therapeutic agents through a unique microcatheter with an expandable tip that creates a pressure gradient, driving therapeutic agents deeply into the tumor while minimizing backflow that might otherwise damage healthy tissue. The Surefire Infusion System enables physicians to target tumors with superior accuracy, control and protection. The Surefire Infusion Systems and Surefire Precision have received regulatory approval in the U.S., Europe, Canada, Mexico and Brazil. For more information, please visit www.surefiremedical.com.
Media Contact: Edna Kaplan KOGS Communication 781-639-1910 [email protected]


Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



